Marginal Dose and Tumor Regression after Stereotactic Irradiation for Uveal Melanoma

1997 ◽  
pp. 114-120 ◽  
Author(s):  
M. Zehetmayer ◽  
M. Georgopoulos ◽  
I. Ruhswurm ◽  
S. Toma-Bst�ndig ◽  
K. Kitz ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Tumor Regression ◽  
Stereotactic Irradiation

Ultrasound Biomicroscopy Documented Anterior Uveal Melanoma Regression after Ruthenium-106 Plaque Therapy

2021 ◽  
pp. 1-9
Author(s):  
Biljana Kuzmanović Elabjer ◽  
Mladen Bušić ◽  
Andrej Pleše ◽  
Mirjana Bjeloš ◽  
Daliborka Miletić ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Tumor Regression ◽  
Corneal Thickness ◽  
Case Series ◽  
Ultrasound Biomicroscopy ◽  
Close Monitoring ◽  
Single Institution ◽  
Retrospective Case ◽  
Caucasian Patients

<b><i>Introduction:</i></b> Ultrasound biomicroscopy (UBM) is the only widely used method for the evaluation of anterior uveal melanoma (AUM). <b><i>Objective:</i></b> Documentation of regression of AUM treated with ruthenium-106 (Ru-106) plaque types CCB and CCC using UBM. <b><i>Methods:</i></b> This single institution-based retrospective case series involved 10 Caucasian patients with AUM followed after brachytherapy with UBM from January 2014 until February 2019. The largest prominence of the tumor perpendicular to the sclera or the cornea (including scleral/corneal thickness) (<i>D</i>) and the largest basal dimension (<i>B</i>) were measured in millimeters with UBM for all patients prior to the brachytherapy and at 4-month interval follow-up. Tumor regression was calculated as a percentage of decrease in the initial <i>D</i> and <i>B</i> values. <b><i>Results:</i></b> The study involved 10 patients with a mean age of 64.4 years (yr) (range 46–80 yr). <i>D</i> ranged from 1.82 to 5.5 mm (median 2.99 mm) and <i>B</i> from 2.32 to 12.38 mm (median 4.18 mm). The apical radiation dose in all patients was 100 Gy. The median follow-up was 42.02 months. Regression for <i>D</i> was 21.11 ± 13.66%, 31.09 ± 14.66%, and 34.92 ± 19.86% at 1st, 2nd, and 3rd year of the follow-up, respectively, while for <i>B</i> it was 21.58 ± 16.05%, 28.98 ± 17.71%, and 32.06 ± 18.96%, respectively. Tumor recurrence was documented in 2/10 patients. <b><i>Conclusion:</i></b> The major regression of AUM, treated with Ru-106 plaque types CCB and CCC, was documented in the first 2 years after brachytherapy in our study group. In the following years, only minimal regression was documented that warns of the need for close monitoring and active search for local recurrences.

Stereotactic Irradiation of Uveal Melanoma with the Leksell Gamma Unit

2015 ◽  
pp. 47-55 ◽  
Author(s):  
Martin Zehetmayer ◽  
Rupert Menapace ◽  
Klaus Kitz ◽  
Adolf Ertl ◽  
Karin Strenn ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Stereotactic Irradiation

Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma

Ophthalmology ◽  
2017 ◽  
Vol 124 (10) ◽  
pp. 1532-1539 ◽  
Author(s):  
Prithvi Mruthyunjaya ◽  
Michael I. Seider ◽  
Sandra Stinnett ◽  
Amy Schefler ◽  
Prithvi Mruthyunjaya ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profile ◽  
Uveal Melanoma ◽  
Expression Profile ◽  
Tumor Regression ◽  
Regression Rate ◽  
Plaque Radiotherapy ◽  
Iodine 125

Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8598-8598 ◽  
Author(s):  
Richard D. Carvajal ◽  
Grazia Ambrosini ◽  
Jedd D. Wolchok ◽  
Paul B. Chapman ◽  
Mark Andrew Dickson ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Clinical Benefit ◽  
Tumor Regression ◽  
Mapk Pathway ◽  
Rank Correlation ◽  
Metastatic Tumor ◽  
Prior Therapy ◽  
Activating Mutations ◽  
Pathway Inhibition ◽  
Tumor Biopsies

8598 Background: Functionally activating mutations (mut) in Gnaq or Gna11, genes that encode for widely expressed G-protein alpha subunits, are early oncogenic events in uveal melanoma (UM) development and result in activation of the MAPK pathway. We previously demonstrated effective pathway inhibition with selumetinib (AZD6244, ARRY-142866) in UM cell lines, with decreased viability associated with pERK and cyclinD1 suppression (Ambrosini, AACR 2010). Methods: Using paired metastatic tumor biopsies from patients (pts) with radiographically progressing UM treated with selumetinib 75 mg BID on a phase II trial (NCT01143402), we correlated MAPK pathway inhibition with radiographic tumor regression and clinical benefit. Biopsies were performed at baseline and after 14 +/-1 days of treatment. Western blotting was performed for pERK and cyclinD1, and quantitated by densitometry. Response (RECIST 1.1) was assessed at baseline, week (wk) 4, wk 8, and q8wks subsequently. Radiographic regression was defined as greatest percentage shrinkage from baseline. Clinical benefit was defined as RECIST response or stable disease ≥16wks. Results: Paired tumor biopsies were assayed from 18 pts: median age 60 (range 47-81), M:F 11:7, median 1 prior therapy (range 0-2), 17 with liver involvement, Gnaq mut:Gna11 mut:wild-type 8:9:1. Radiographic regression was observed in 5 pts, with 2 achieving partial responses. 4 pts were on study ≥16wks (16+, 20, 25, 31 wks), with one currently on study at 11+ wks. Median pERK and cyclinD1 as measured by densitometry decreased by 48% (p=.03) and 76% (p=.03), respectively. Radiographic regression correlated with suppression of pERK (Spearmen’s rank correlation; p=0.04) but not cyclinD1 (p=0.38). A trend towards pERK suppression correlating with clinical benefit was observed (p=.07) with each of the 5 pts achieving PR or SD ≥16wks having a decrease of ≥30% in pERK from baseline. Conclusions: Selumetinib can inhibit pERK and cyclinD1 in UM and can result in tumor shrinkage. Sustained inhibition of pERK inhibition at day 14 may be predictive of benefit. Further evaluation of MEK inhibition in this disease is warranted.

A linac-based stereotactic irradiation technique of uveal melanoma

2001 ◽  
Vol 61 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Karin Dieckmann ◽  
Joachim Bogner ◽  
Dietmar Georg ◽  
Martin Zehetmayer ◽  
Gerhard Kren ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Stereotactic Irradiation

scholarly journals Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Rui Fang ◽  
Heng Wang ◽  
Yang Li ◽  
Yue-Ming Liu ◽  
Wen-Bin Wei
Keyword(s):  
Uveal Melanoma ◽  
Tumor Regression ◽  
Chi Square ◽  
Basal Diameter ◽  
Regression Rate ◽  
Chi Square Test ◽  
Iodine 125 ◽  
Plaque Brachytherapy ◽  
Uveal Melanomas

Abstract Background Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. Methods Adult uveal melanoma patients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. Results A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). Conclusion Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.

Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma

2021 ◽  
Author(s):  
Timothy T. Xu ◽  
Jose S. Pulido ◽  
Ian F. Parney ◽  
Cristiane M. Ida ◽  
Lauren A. Dalvin ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Tumor Localization ◽  
Fiducial Markers ◽  
Stereotactic Irradiation

Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9094-9094 ◽  
Author(s):  
Adil Daud ◽  
Harriet M. Kluger ◽  
Gerald Edelman ◽  
Michael S. Gordon ◽  
Frauke Schimmoller ◽  
...  
Keyword(s):  
Overall Survival ◽  
Uveal Melanoma ◽  
Tumor Regression ◽  
Tumor Burden ◽  
Open Label ◽  
Vegf Signaling ◽  
Common Grade ◽  
Melanoma Treatment ◽  
Grade 3 ◽  
Tumor Types

9094 Background: MET and VEGF signaling are implicated in angiogenesis, invasion, and metastasis, and upregulation of MET as a consequence of GNAQ/GNA11 mutation has been implicated in uveal melanoma. Historical rates of median overall survival (OS) in patients (pts) with metastatic uveal melanoma range from 6-9 months (mos). A RDT evaluated activity and safety of cabozantinib, a MET and VEGFR2 inhibitor, in 9 tumor types including a metastatic melanoma cohort where 55% and 5% of pts experienced objective tumor regression and confirmed partial response, respectively (J. Clin. Oncol. 30, 2012 (suppl; abstr. 8531)). Here we report on the longer term followup of metastatic uveal melanoma pts enrolled to this cohort. Methods: Eligible pts were required to have progressive measurable disease per RECIST. Pts received cabozantinib at 100 mg po qd over a 12 wk Lead-in stage. Tumor response (mRECIST) was assessed q6 wks. Treatment ≥ wk 12 was based on response: pts with PR continued open-label cabozantinib, pts with SD were randomized to cabozantinib vs placebo, and pts with PD discontinued. Pts were followed for overall survival. Results: 23 of 77 pts enrolled in the melanoma cohort had the uveal subtype. Median age was 65 yrs; median prior regimens was 1 (range 0-5). Tumor mutation status was determined for 10/23 pts. 9/10 harbored either a GNAQ or GNA11 mutation, while GNA11 status was unknown for one pt. Pts had substantial tumor burden; median sum of the longest diameter of target lesions was 11.9 cm (range, 2-37.2). Median follow-up was 26.5 mos. (range 21.7-33.8). Median PFS from Study Day 1 was 4.8 mos. The estimate of PFS at month 6 (PFS6) was 41% and median OS was 12.6 mos. Most common Grade 3/4 AEs were HTN (13%), abdominal pain (9%), hypokalaemia (9%), hyperbilirubinaemia (9%) and increased lipase (9%). Conclusions: Cabozantinib is active in pts with metastatic uveal melanoma. Treatment with cabozantinib is associated with encouraging progression-free and overall survival. The safety profile of cabozantinib was comparable to that of other VEGFR TKIs. A randomized Phase 2 study is planned comparing cabozantinib to temozolomide plus dacarbazine in pts with uveal melanoma. Clinical trial information: NCT00940225.

Evaluation of Tumor Regression and Other Prognostic Factors for Early and Late Metastasis after Proton Irradiation of UVeal Melanoma

Ophthalmology ◽  
1989 ◽  
Vol 96 (10) ◽  
pp. 1566-1573 ◽  
Author(s):  
Robert J. Glynn ◽  
Johanna M. Seddon ◽  
Evangelos S. Gragoudas ◽  
Kathleen M. Egan ◽  
Lots J. Hart
Keyword(s):  
Prognostic Factors ◽  
Uveal Melanoma ◽  
Proton Irradiation ◽  
Tumor Regression ◽  
Late Metastasis

scholarly journals Long‐term experience of one‐day stereotactic irradiation in patients with uveal melanoma

2022 ◽  
Vol 100 (S267) ◽  
Author(s):  
Alena Furdova ◽  
Miron Sramka ◽  
Bozena Smolkova ◽  
Robert Furda ◽  
Denisa Jurenova ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Stereotactic Irradiation ◽  
Long Term Experience
Sign in / Sign up

Export Citation Format

Share Document